← back to search

Christine Hunter

Australian Hearing · AU
Area of research
Neurology · Cellular and Molecular Neuroscience
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Genetic Neurodegenerative Diseases, and Botulinum Toxin and Related Neurological Disorders.
h-index
43
citations
8,085
works
117
NIH funding
primary concept
email

Recent publications

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression
JAMA 2021cited by 156position: middledoi
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
JAMA Neurology 2020cited by 140position: middledoi
Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis.
2020cited by 7position: contributordoi
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
The Lancet Neurology 2019cited by 136position: middledoi
Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis
Parkinsonism & Related Disorders 2019cited by 13position: middledoi
Onabotulinum toxin-A injections for sleep bruxism
Neurology 2018cited by 93position: middledoi
National randomized controlled trial of virtual house calls for Parkinson disease
Neurology 2017cited by 219position: middledoi
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea
JAMA Neurology 2017cited by 211position: middledoi
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease
JAMA 2016cited by 395position: middledoi
National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers
Telemedicine Journal and e-Health 2016cited by 65position: middledoi
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits
Movement Disorders 2015cited by 59position: middledoi
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS)
JAMA Neurology 2015cited by 46position: middledoi
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
JAMA Neurology 2014cited by 389position: middledoi
Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease
Neurology 2012cited by 111position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

William G. Ondo · Houston Methodist2 papers (2012–2018)Joseph Jankovic · Phillips University2 papers (2017–2018)Christina Vaughan · University of Colorado Denver1 papers (2017–2017)Jerald Simmons · Comprehensive Cardiovascular1 papers (2018–2018)Vera I. Hashem · Houston Methodist1 papers (2018–2018)Walter J. Jermakowicz · University of Louisville1 papers (2019–2019)Christopher Kenney · Acorda Therapeutics (United States)1 papers (2012–2012)Theresa Zesiewicz · University of South Florida1 papers (2012–2012)Claudia M. Testa · Virginia Commonwealth University1 papers (2017–2017)Danielle S. Abraham · Georgetown University1 papers (2019–2019) · 1 papers (2017–2017)Clement T. Loy · Westmead Hospital1 papers (2017–2017) · 1 papers (2020–2020)Kelvin L. Chou · Elsevier, Inc.1 papers (2020–2020)Jason M. Schwalb · Indianapolis Zoo1 papers (2020–2020)Joohi Jimenez-Shahed · Neurology, Inc1 papers (2020–2020)Michele K. York · Michael E. DeBakey VA Medical Center1 papers (2020–2020)Sneha Mantri · Duke University1 papers (2020–2020)David K. Simon · Beth Israel Deaconess Medical Center1 papers (2020–2020)Jason M. Schwalb · Neurological Surgery1 papers (2019–2019)